Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy

Clinical and Experimental Immunology

Volumn 106, Issue 2, 1996, Pages 197-202

  Kahaly, G ^a   Pitz, S ^a   Muller Forell W ^a   Hommel, G ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Graves' ophthalmopathy; immunoglobulin therapy

Indexed keywords

IMMUNOGLOBULIN; PREDNISOLONE; THYROID ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029849042     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-854.x     Document Type: Article

References (28)

1. Schwartz SA. Intravenous immunoglobulin for autoimmune disorders. J Clin Immunol 1990; 10:81 89.
2. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107 16.
3. Ratko TA, Burnett DA, Foulke GE et al., and the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously administered Immunoglobulin Preparations. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273:1865 70.
4. Rossi F, Kazatschkine MD. Anti-idiotypes against autoantibodies in pooled normal human polyspecific immunoglobulins. J Immunol 1989; 143:4104 9.
5. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991; 328:25-28.
6. v.d. Gaag R, Schmidt ED, Koorneef L. Retrobulbar histology and immunohistochemistry in endocrine ophthalmopathy. In: Kahaly G, ed. Endocrine ophthalmopathy. Molecular, immunological and clinical aspects. Basel: Karger, 1993:1 10.
7. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15:788 830.
8. Fells P. Thyroid-associated eye disease: clinical management. Lancet 1991; 338:29 32.
9. Dwyer JM, Benson EM, Currie JN et al. Intravenously administered IgG for the treatment of thyroid eye disease. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:387 94.
10. Antonnelli A, Saracino A, Alberti B et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol 1992; 126:13 23.
11. Antonelli A, Navarrane A, Palla R et al. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. Thyroid 1994; 4:399 408.
12. Anon. Classification of eye changes of Graves' disease. Thyroid 1992; 2:235 6.
13. Kahaly G, Sehrezenmeir J, Krause U et al. Ciclosporin and prednisone vs prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986; 16:415 22.
14. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85:620 5.
15. Kaveri SV, Mouthon L, Kazatschkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol. Neurosurg Psychiatry 1994; 57(Suppl.):6 8.
16. Vassilev T, Gelin C, Kaveri SV et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins. IVIG). Clin Exp Immunol 1993; 92:369 72.
17. Blasczyk R, Westholf U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341:789 90.
18. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602 7.
19. Achiron A, Margalit R, Hershkovivz R et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. J Clin Invest 1994; 93:600 5.
20. Andersson V, Bjork L, Skansen-Saphir U et al. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21 42.
21. Schaik IN, Vermeulen M, Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol, Neurosurg Psychiatry 1994; 57(Suppl.):15 17.
22. Aukrust P, Froland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136 43.
23. Shimozato T, Iwata M, Kawada H et al. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 1991; 72:497 501.
24. Just M, Kahaly G, Higer HP et al. Graves' ophthalmopathy: role of MR imaging in radiation therapy. Radiology 1991; 179:187 90.
25. Hiromatsu Y, Kojima K, Ishisaka N et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992; 2:299 305.
26. Horowitz B, Prince AM, Horowitz MS et al. Viral safety of solvent-detergent treated blood products. Dev Biol Strand 1993; 81:147 61.
27. Schiff RI. Transmission of viral infections through intravenous immune globulin. Editorial. N Engl J Med 1994; 331:1649 50.
28. Gardulf A, Andersen V, Björkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365 9.